Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as
monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in
combination with Rituximab in relapsed/refractory B-cell Lymphoma.
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of
QN-019a in patients with relapsed/refractory B-cell lymphoma or B-ALL. Up to 22-36 patients
will be enrolled.